Tumor necrosis factor-α: A promising therapeutic target for asthma?

BioDrugs

Volumn 21, Issue 6, 2007, Pages 345-349

  Heffler, Enrico ^a,b,c   Berry, Mike ^d   Pavord, Ian D ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c GLENFIELD HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Asthma, treatment; Tumour necrosis factor alpha, general; Tumour necrosis factor antagonists, therapeutic use

Indexed keywords

ADALIMUMAB; AMIDINOHYDRAZONE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; MARIMASTAT; METALLOPROTEINASE INHIBITOR; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ASTHMA; ASTHMA; BIOLOGICAL ACTIVITY; BREATHING MUSCLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG TARGETING; HEALTH CARE COST; HISTAMINE RELEASE; HUMAN; INJECTION SITE REACTION; INNATE IMMUNITY; LUNG; MAST CELL; MORPHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOOTH MUSCLE; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 36348966537     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721060-00002     Document Type: Review

References (53)

1. Global Initiative for Asthma. Global strategy for asthma management and preven-tion. NHLBI/WHO workshop report. Geneva: NHLBI/WHO, 1995
2. British guideline on the management of asthma. Thorax 2003; 58 Suppl. 1: i1-94
3. Holgate ST, Holloway J, Wilson S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117 (3): 496-506
4. Tulic MK, Hamid Q. New insights into the pathophysiology of the small airways in asthma. Clin Chest Med 2006; 27 (1): 41-52, vi
5. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160 (3): 1001-8
6. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22 (3): 470-7
7. Busse WW, Banks-Schlegel S, Wenzel SE. Pathophysiology of severe asthma. J Allergy Clin Immunol 2000; 106 (6): 1033-42
8. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23 (5): 723-9
9. Wenzel SE. Severe asthma in adults. Exp Lung Res 2005; 31 Suppl. 1: 22
10. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005; 365 (9463): 974-6
11. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3 (10): 831-44
12. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354 (7): 697-708
13. Bodey KJ, Semper AE, Redington AE, et al. Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy 1999; 54 (10): 1083-93
14. Wilson SJ, Wallin A, Della-Cioppa G, et al. Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001; 164 (6): 1047-52
15. Churg A, Dai J, Tai H, et al. Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002; 166 (6): 849-54
16. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95 (5): 2409-15
17. O'Malley WE, Achinstein B, Shear MJ. Journal of the National Cancer Institute, Vol. 29, 1962: action of bacterial polysaccharide on tumors: II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. Nutr Rev 1988; 46 (11): 389-91
18. Russo C, Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 2005; 109 (2): 135-42
19. Eigler A, Sinha B, Hartmann G, et al. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18 (10): 487-92
20. Tavares JL, Wangoo A, Dilworth P, et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997; 91 (1): 31-9
21. Tracey KJ. Suppression of TNF and other proinflammatory cytokines by the tetravalent guanylhydrazone CNI-1493. Prog Clin Biol Res 1998; 397: 335-43
22. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370 (6486): 218-20
23. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 2000; 9 (3): 497-514
24. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-{alpha} in asthma. Am J Respir Crit Care Med 2006; 174 (7): 753-62
25. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344 (12): 907-16
26. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126 (2): 402-13
27. Evereklioglu C. Managing the symptoms of Behcet's disease. Expert Opin Pharmacother 2004; 5 (2): 317-28
28. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50 (7): 2264-72
29. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60 (12): 1012-8
30. Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53 (1): 45-53
31. Zheng Y, Saftig P, Hartmann D, et al. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004; 279 (41): 42898-906
32. Davis JM, Narachi MA, Alton NK, et al. Structure of human tumor necrosis factor alpha derived from recombinant DNA. Biochemistry 1987; 26 (5): 1322-6
33. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262 (15): 6951-4
34. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990; 87 (8): 3127-31
35. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336 (15): 1066-71
36. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10 (5): 471-80
37. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002; 57 (9): 774-8
38. van Overveld FJ, Jorens PG, Rampart M, et al. Tumour necrosis factor stimulates human skin mast cells to release histamine and tryptase. Clin Exp Allergy 1991; 21 (6): 711-4
39. Coward WR, Okayama Y, Sagara H, et al. NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J Immunol 2002; 169 (9): 5287-93
40. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152 (1): 76-80
41. Renzetti LM, Paciorek PM, Tannu SA, et al. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exp Ther 1996; 278 (2): 847-53
42. Amrani Y, Martinet N, Bronner C. Potentiation by tumour necrosis factor-alpha of calcium signals induced by bradykinin and carbachol in human tracheal smooth muscle cells. Br J Pharmacol 1995; 114 (1): 4-5
43. Amrani Y, Panettieri Jr RA, Frossard N, et al. Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am J Respir Cell Mol Biol 1996; 15 (1): 55-63
44. Nakatani Y, Nishimura Y, Nishiuma T, et al. Tumor necrosis factor-alpha augments contraction and cytosolic Ca(2+) sensitivity through phospholipase A(2) in bovine tracheal smooth muscle. Eur J Pharmacol 2000; 392 (3): 175-82
45. Parris JR, Cobban HJ, Littlejohn AF, et al. Tumour necrosis factor-alpha activates a calcium sensitization pathway in guinea-pig bronchial smooth muscle. J Physiol 1999; 518 (Pt 2): 561-9
46. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002; 14 (6): 477-92
47. Franchimont D, Martens H, Hagelstein MT, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84 (8): 2834-9
48. Sullivan DE, Ferris M, Pociask D, et al. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 2005; 32 (4): 342-9
49. Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122 (1): 103-11
50. Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168 (11): 1308-11
51. Michel O, Ginanni R, Duchateau J, et al. Domestic endotoxin exposure and clinical severity of asthma. Clin Exp Allergy 1991; 21 (4): 441-8
52. Weiss ST, Shore S. Obesity and asthma: directions for research. Am J Respir Crit Care Med 2004; 169 (8): 963-8
53. Bruce C, Thomas PS. The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 2005; 205 (2): 126-32